EP 1418919 A4 20070613 - THE USE OF 5 FLUOROURCIL, DELIVERED BY INOTOPHORESIS AS AN INHIBITOR OF CELL PROLIFERATION IN THE EYE, BULBAR AND PALPEBRAL CONJUNCTIVA, EYELID, PERI-ORBITAL SOFT TISSUES AND SKIN
Title (en)
THE USE OF 5 FLUOROURCIL, DELIVERED BY INOTOPHORESIS AS AN INHIBITOR OF CELL PROLIFERATION IN THE EYE, BULBAR AND PALPEBRAL CONJUNCTIVA, EYELID, PERI-ORBITAL SOFT TISSUES AND SKIN
Title (de)
VERWENDUNG VON 5-FLUOROURACIL, VERABREICHT DURCH INOTOPHORESE, ALS HEMMER DER ZELLPROLIFERATION IM AUGE, DER BULBÄREN UND PALPEBRALEN KONJUNKTIVA, DEM AUGENLID, DEM PERIORBITALEN GEWEBEN UND DER HAUT
Title (fr)
UTILISATION DE 5 FLUOROURCIL, ADMINISTRE PAR IONTOPHORESE EN TANT QU'INHIBITEUR DE LA PROLIFERATION CELLULAIRE DANS L'OEIL, LA CONJONCTIVE BULBAIRE ET PALPEBRALE, LA PAUPIERE, LES TISSUS MOUS ET LA PEAU PERIORBITAIRES
Publication
Application
Priority
- US 0222860 W 20020719
- US 30678801 P 20010720
Abstract (en)
[origin: WO03007798A2] A method for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular area having a neoplastic angiogenic, fibroblastic, and/or immunosuppressive irregularity; providing a 5' fluorouracil based medicament, wherein the 5' fluorouracil based medicament is capable of inhibiting DNA synthesis; associating a therapeutically effective concentration of the 5' fluorouracil based medicament with the affected ocular area of the living subject; and decreasing the neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularity of the living subject.
IPC 8 full level
A61K 31/513 (2006.01); C07D 239/553 (2006.01); A61K 9/08 (2006.01); A61N 1/30 (2006.01); A61P 27/02 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP)
A61K 31/513 (2013.01); A61N 1/30 (2013.01); A61P 27/02 (2017.12); A61P 35/00 (2017.12)
Citation (search report)
- [XY] WO 9940967 A1 19990819 - HADASIT MED RES SERVICE [IL], et al
- [X] WO 0051620 A1 20000908 - VITREO RETINAL TECHNOLOGIES IN [US]
- [Y] EP 0927560 A1 19990707 - OPTISINVEST [AN]
- [Y] US 5298017 A 19940329 - THEEUWES FELIX [US], et al
- [Y] JP H0549702 A 19930302 - TEIJIN LTD
- [PY] WO 0191853 A1 20011206 - BIOPHORETIC THERAPEUTIC SYSTEM [US]
- [E] WO 03007961 A1 20030130 - IOMED INC [US], et al
- See references of WO 03007798A2
Designated contracting state (EPC)
DE FR GB IT
DOCDB simple family (publication)
WO 03007798 A2 20030130; WO 03007798 A3 20030619; AU 2002316724 A1 20030303; EP 1418919 A2 20040519; EP 1418919 A4 20070613; JP 2004535462 A 20041125
DOCDB simple family (application)
US 0222860 W 20020719; AU 2002316724 A 20020719; EP 02747054 A 20020719; JP 2003513412 A 20020719